Glimepiride (Monograph)

Drug class: Sulfonylureas

Medically reviewed by Drugs.com on Apr 10, 2025. Written by ASHP.

Introduction

Antidiabetic agent; sulfonylurea.¹

Uses for Glimepiride

Type 2 Diabetes Mellitus

Used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.¹ ⁵⁴

Used as monotherapy or in combination with other antidiabetic agents.¹ ⁵ ⁷ ¹¹ ²⁰ ²² ⁴⁶ ⁴⁷ ⁴⁸ ⁵⁴ ⁹⁷ ¹⁰² ¹⁰³ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹¹⁷ ⁷⁰⁷ ⁷⁰⁸

Commercially available as a single entity preparation and in fixed combination with pioglitazone (Duetact).¹ ¹¹⁷

Guidelines from the American Diabetes Association (ADA) and other experts generally recommend that use of sulfonylureas for the treatment of type 2 diabetes mellitus be limited or discontinued due to increased risk of weight gain and hypoglycemia.⁷⁰⁷ ⁷⁰⁸ Sulfonylureas may be considered in patients with access or cost barriers to other antidiabetic agents.⁷⁰⁸ When used, these guidelines recommend the lowest possible dosage.⁷⁰⁷ When selecting a treatment regimen, consider factors such as cardiovascular and renal comorbidities, drug efficacy and adverse effects, hypoglycemic risk, presence of overweight or obesity, cost, access, and patient preferences.⁷⁰⁷ ⁷⁰⁸ Weight management should be included as a distinct treatment goal and other healthy lifestyle behaviors should also be considered.⁷⁰⁷ ⁷⁰⁸

Not indicated for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.¹

Glimepiride Dosage and Administration

General

Patient Monitoring

Monitor patients with regular laboratory evaluations (including fasting blood or plasma glucose determinations) to determine therapeutic response and minimum effective dosage of glimepiride.¹
Following initiation and at dosage titration, monitor HbA_1c approximately every 3–6 months to determine patient’s continued response to therapy.¹ ⁷⁰⁷ ⁷⁰⁸

Dispensing and Administration Precautions

Based on the Institute for Safe Medication Practices (ISMP), glimepiride is a high-alert medication that has a heightened risk of causing significant patient harm when used in error.⁷⁰⁹

Administration

Oral Administration

Glimepiride: Administer once daily with breakfast or first main meal of the day.¹ ⁵ ⁶

Fixed combination of glimepiride and pioglitazone: Administer once daily with the first main meal.¹¹⁷

Adjust dosage according to tolerance and fasting glucose determinations.¹

Use lowest effective dosage (either as monotherapy or in combination regimens) to reduce both fasting glucose concentrations and HbA_1c values to normal or near normal.¹ ¹⁷ ²⁴ ²⁸

Dosage

Adults

Type 2 Diabetes Mellitus

Glimepiride Monotherapy

Oral

Initially, 1 or 2 mg of glimepiride once daily before breakfast or first main meal.¹ In patients at risk for hypoglycemia, (e.g., geriatric patients), initial dosage should be 1 mg once daily.¹

In patients receiving 1 mg daily, increase dosage to 2 mg daily after 1–2 weeks if adequate glycemic control has not been achieved.¹ After reaching 2 mg dosage, increase dosage in increments of no more than 1 or 2 mg daily at 1- to 2-week intervals up to a maximum of 8 mg once daily.¹

When transferring from most sulfonylurea antidiabetic agents to glimepiride, a transition period is generally not required.¹ Since an exaggerated hypoglycemic response may occur during transition from a sulfonylurea with a prolonged half-life to glimepiride, monitor patients closely for hypoglycemia during the initial 1-2 weeks of the transition period.¹

Glimepiride/Pioglitazone Fixed-combination Therapy

Oral

Select initial dosage based on patient’s current dosage of glimepiride (or another sulfonylurea agent) and/or pioglitazone.¹¹⁷

Patients currently receiving glimepiride monotherapy: Usual initial dosage is 2 or 4 mg of glimepiride and 30 mg of pioglitazone once daily.¹¹⁷

Patients currently receiving pioglitazone monotherapy: Usual initial dosage is 2 mg of glimepiride and 30 mg of pioglitazone once daily.¹¹⁷

Patients switching from concurrent therapy with separate glimepiride and pioglitazone preparations: Initiate the fixed combination at doses that are as close as possible to the dose of glimepiride and pioglitazone already being taken; adjust subsequent dosage based on response.¹¹⁷

Patients transferring from monotherapy with other sulfonylureas or from combination therapy with pioglitazone and a sulfonylurea other than glimepiride: Initially, 2 mg of glimepiride and 30 mg of pioglitazone once daily; adjust subsequent dosage based on response.¹¹⁷

Special Populations

Hepatic Impairment

Glimepiride monotherapy: No specific population dosage recommendations at this time.¹

Fixed combination of glimepiride and pioglitazone: No specific population dosage recommendations at this time; use with caution in patients with liver disease.¹¹⁷

Renal Impairment

Glimepiride monotherapy: Initially, 1 mg once daily.¹ Titrate dosage upward based on fasting glucose concentrations; conservative titration scheme recommended.¹

Fixed combination of glimepiride and pioglitazone: No specific population dosage recommendations at this time.¹¹⁷ To minimize risk of hypoglycemia, initial dosage, dosage increments, and maintenance dosage should be conservative.¹¹⁷

Geriatric Patients

Geriatric individuals may be particularly sensitive to the hypoglycemic effects of glimepiride.¹

Glimepiride monotherapy: Initially, 1 mg once daily.¹ Titrate dosage upward with care.¹ Conservative initial and maintenance dosages recommended.¹

Fixed combination of glimepiride and pioglitazone: No specific population dosage recommendations at this time; initial dosage, dosage increments, and maintenance dosage should be conservative.¹¹⁷

Patients with Heart Failure

Fixed combination of glimepiride and pioglitazone: Initiate glimepiride/pioglitazone fixed-combination at lowest recommended dosage; use fixed-combination preparation only after patient has received pioglitazone 15 mg once daily as monotherapy and has safely tolerated dosage titration to 30 mg once daily.¹¹⁷ If subsequent dosage adjustment required, closely monitor for weight gain, edema, or other manifestations of heart failure exacerbation.¹¹⁷

Cautions for Glimepiride

Contraindications

Known hypersensitivity to glimepiride or any ingredient in formulation.¹
Hypersensitivity to sulfonamide derivatives.¹

Warnings/Precautions

Hypoglycemia

Can cause severe hypoglycemia; ability to concentrate and react may be impaired as a result.¹ These impairments may present risk in situations where these abilities are important, such as driving or operating machinery.¹ Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death.¹

Appropriate patient selection and careful attention to dosage are important to avoid glimepiride-induced hypoglycemia.¹ Geriatric patients, debilitated, or malnourished patients, or those with adrenal, pituitary, renal, or hepatic impairment may be particularly susceptible to hypoglycemia.¹ Use caution when initiating and increasing dosage in patients predisposed to hypoglycemia.¹ Hypoglycemia more likely to occur when caloric intake is deficient, after severe or prolonged exercise, and when alcohol is ingested.¹ Hypoglycemia may be more difficult to recognize in geriatric patients, in patients with autonomic neuropathy, and in those receiving β-adrenergic blocking agents or other sympatholytic agents.¹ In these situations, severe hypoglycemia may occur before patient is aware of hypoglycemia.¹

Inform patients and responsible family members of risks of hypoglycemia, symptoms and treatment of hypoglycemic reactions, and conditions that predispose to the development of such reactions.¹

Hypersensitivity Reactions

Postmarketing reports of hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome.¹

If hypersensitivity reaction suspected, promptly discontinue glimepiride, assess for other potential causes of reaction, and initiate alternate treatment for diabetes mellitus.¹

Hemolytic Anemia

Sulfonylureas, including glimepiride, can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.¹ Hemolytic anemia reported in patients receiving glimepiride with no known history of G6PD deficiency.¹

Use caution in patients with G6PD deficiency and consider use of non-sulfonylurea alternative.¹

Increased Risk of Cardiovascular Mortality

Oral hypoglycemic drugs reported to be associated with increased cardiovascular mortality as compared to diet alone or diet plus insulin.¹

Inform patients of potential risk and advantages of glimepiride and of alternative therapy.¹

Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride.¹

Use of Fixed Combinations

When used in fixed combination with pioglitazone or other drugs, consider the cautions, precautions, and contraindications associated with pioglitazone or other concomitant agent(s).¹¹⁷

Specific Populations

Pregnancy

Available data from small number of published studies and decades of postmarketing experience have not identified any drug associated risk for major birth defects, miscarriage, or adverse maternal outcomes.¹ Sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia.¹ Prolonged hypoglycemia (lasting 4—10 days) reported in neonates born to mothers receiving sulfonylureas at time of delivery and with use of agents with prolonged half-life.¹

Poorly controlled diabetes mellitus during pregnancy carries risks for mother and fetus.¹ Due to risk of prolonged hypoglycemia in neonates born to mothers receiving a sulfonylurea at time of delivery, glimepiride should be discontinued at least 2 weeks before expected delivery.¹ Observe newborns for symptoms of hypoglycemia and respiratory distress and manage accordingly.¹

Lactation

No information regarding presence in human milk or effect on milk production.¹ Distributed into milk in rats.¹ Developmental and health benefits of breastfeeding should be considered along with any potential adverse effects on breast-fed child from glimepiride or from underlying maternal condition.¹ Breast-fed infants of lactating women using glimepiride should be monitored for symptoms of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures).¹

Pediatric Use

Use not recommended because of adverse effects on body weight and hypoglycemia.¹

Geriatric Use

No substantial differences in safety, efficacy, or pharmacokinetics relative to younger adults, but increased sensitivity cannot be ruled out.¹

Possible increased risk of adverse effects due to age-related decreases in renal function.¹

Increased risk of hypoglycemia; may be difficult to recognize in geriatric patients.¹

Use caution when initiating and increasing dosage of glimepiride in geriatric patients.¹

Hepatic Impairment

Pharmacokinetics of glimepiride not adequately evaluated in patients with hepatic impairment.¹

Renal Impairment

Increased risk of hypoglycemia; conservative dosing recommended.¹

Obesity

Lower maximum plasma concentration (C_max) and AUC than patients with normal body weight with similar time to maximum plasma concentration (T_max), clearance, and volume of distribution.¹

Common Adverse Effects

Most common adverse effects (≥5% and more common than placebo): Hypoglycemia, headache, nausea, dizziness.¹

Drug Interactions

Metabolized by CYP2C9.¹

Drugs Affecting Hepatic Microsomal Enzymes

Pharmacokinetic interactions likely with drugs that are inhibitors and inducers of CYP2C9; possible alteration in metabolism of glimepiride.¹

Protein-bound Drugs

Potential pharmacokinetic interaction (increased hypoglycemic effect).¹

Close observation recommended when initiating or discontinuing concomitant therapy with a highly protein-bound drug.¹

Drugs Affecting Glucose Metabolism

A number of medications affect glucose metabolism and may require glimepiride dosage adjustment and close monitoring for hypoglycemia or worsening glycemic control.¹

A number of medications reduce the glucose-lowering effect of glimepiride, leading to worsening glycemic control.¹

Signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as β-adrenergic blocking agents and clonidine.¹

Close observation recommended when initiating or discontinuing concomitant therapy.¹

Specific Drugs

Drug	Interaction	Comments
ACE inhibitors	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Alcohol (acute and chronic ingestion)	May potentiate or weaken hypoglycemic effect¹
Anabolic steroids and androgens	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Atypical antipsychotics (i.e., clozapine, olanzapine)	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Azole antifungals	Miconazole (oral): Increased hypoglycemic effect; severe hypoglycemia reported¹ Fluconazole: Increased plasma concentration of glimepiride; potential for increased hypoglycemic effect¹	Miconazole: Not known whether interaction occurs with other antifungal dosage forms¹ Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
β-Adrenergic blocking agents (e.g., propranolol)	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹ Increased peak plasma concentrations and half-life and decreased clearance of glimepiride with concomitant propranolol¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹ Signs of hypoglycemia may be reduced or absent¹
Barbiturates	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Chloramphenicol	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Clarithromycin	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Colesevelam	Reduced maximum plasma concentration and total exposure of glimepiride¹	Administer glimepiride at least 4 hours prior to colesevelam¹
Corticosteroids	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Coumarin anticoagulants (e.g., warfarin)	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹ No change in warfarin protein binding with concomitant administration but slight decrease in pharmacodynamic response¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹ No clinically important pharmacokinetic interaction with warfarin reported¹
Cyclophosphamide	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Danazol	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Diazoxide	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Disopyramide	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Diuretics (e.g., thiazides)	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Estrogens	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Fibrates	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Fluoxetine	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Glucagon	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
H₂-receptor antagonists (e.g., cimetidine, ranitidine)	Absorption and disposition of glimepiride not altered¹
Hormonal contraceptives	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Isoniazid	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Laxatives	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
MAO inhibitors	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Nicotinic acid	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
NSAIAs	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Pentoxifylline	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Phenothiazines	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Phenytoin	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Pramlintide acetate	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Probenecid	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Protease inhibitors	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Quinolones	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Rifampin	Rifampin may induce metabolism of glimepiride, causing decreased plasma concentrations of glimepiride, which may lead to worsening glycemic control¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Salicylates (e.g., aspirin)	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹ Possible decreased peak plasma concentrations and AUC of glimepiride¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Somatostatin analogs	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Somatropin	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Sulfonamides	Highly protein-bound drugs may displace glimepiride from plasma proteins and potentiate hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Sympathomimetic agents	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹
Tetracyclines	Potential for increased hypoglycemic effect¹	Observe carefully for hypoglycemic effects when initiating concomitant therapy or loss of glycemic control when discontinuing such therapy¹
Thyroid hormones	Potential for decreased hypoglycemic effect¹	Observe carefully for loss of glycemic control when initiating concomitant therapy or hypoglycemic effects when discontinuing such therapy¹

Glimepiride Pharmacokinetics

Absorption

Bioavailability

Peak blood concentrations attained within 2–3 hours.¹

Onset

Time to maximum effect about 2–3 hours.¹

Duration

Glucose-lowering effect persists for 24 hours.¹

Food

Food decreases mean peak blood concentrations and AUC by 8 and 9%, respectively.¹

Distribution

Extent

Not known if glimepiride is distributed into human milk.¹

Plasma Protein Binding

>99.5%.¹

Elimination

Metabolism

Metabolized by CYP2C9 and by cytosolic enzymes to active and inactive metabolites.¹

Elimination Route

Excreted in urine (60%) and feces (40%) predominantly as metabolites.¹

Special Populations

Renal impairment: Decreased serum drug concentrations and increased concentrations and half-lives of the metabolites.¹

Geriatric patients: At steady state, lower mean AUC (13%) and increased clearance (11%) compared with younger patients.¹

Obesity: lower maximum plasma concentration and AUC compared to normal body weight.¹

No difference in pharmacokinetics based on sex (when adjusted for body weight) or race.¹

No difference in pharmacokinetics between healthy subjects and patients with diabetes mellitus.¹

Stability

Storage

Oral

Tablets

Glimepiride: Well-closed containers with safety closures at 20–25°C.¹

Actions

Reduces both fasting and postprandial blood glucose concentrations and HbA_1c in a dose-dependent manner.¹ ⁵ ⁶ ²⁰
Lowers blood glucose concentration principally by stimulating postprandial secretion of endogenous insulin from the beta cells of the pancreas.¹ ⁹ ¹⁰ ¹¹ ²⁸ ⁵⁴ Also enhances peripheral sensitivity to insulin.¹ ² ³ ⁵ ⁶ ⁵⁰
Provides overall glycemic control without appreciably increasing fasting insulin secretion.¹ ² ³ ⁵ ⁶ ⁵⁰
Ineffective in the absence of functioning beta cells.¹

Advice to Patients

Inform patients of the potential risks and advantages of glimepiride therapy and of alternative forms of treatment.¹
Inform patients of the importance of taking glimepiride once daily with breakfast or with the first main meal.¹
Inform patients and caregivers of the risk of hypoglycemia.¹ Inform patients of the symptoms and treatment of hypoglycemic reactions and identifying conditions that predispose to the development of such reactions.¹ Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia and that this may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.¹
Inform patients that hypersensitivity reactions may occur with glimepiride and that if a reaction occurs to seek medical treatment and discontinue glimepiride.¹
Inform patients of the importance of regular monitoring of blood glucose (preferably self-monitoring) and of HbA_1c.¹ ⁷⁰⁷ ⁷⁰⁸
Advise patients of the importance of informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹ Advise breast-feeding women taking glimepiride to monitor breast-fed infants for signs of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures).¹
Advise patients of the importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.¹
Inform patients of other important precautionary information.¹

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Glimepiride
Routes	Dosage Forms	Strengths	Brand Names
Oral	Tablets, scored	1 mg*	Glimepiride Tablets
		2 mg*	Glimepiride Tablets
		4 mg*	Glimepiride Tablets

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Glimepiride Combinations
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets	2 mg with Pioglitazone Hydrochloride 30 mg (of pioglitazone)*	Duetact	Takeda
			Glimepiride with Pioglitazone Hydrochloride
		4 mg with Pioglitazone Hydrochloride 30 mg (of pioglitazone)*	Duetact	Takeda
			Glimepiride with Pioglitazone Hydrochloride

References

1. Florida Pharmaceutical Products, Inc.. Glimepiride) tablets prescribing information. Boca Raton, FL; 2024 Oct.

2. Anon. Glimepiride. Drug Future. 1992; 17:774-8.

3. Sato J, Ohsawa I, Oshida Y et al. Comparison between effects of glimepiride and glibenclamide on in vivo insulin action. Intl Congress Series. 1994; 1057:341-4.

5. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract. 1995; 28(Suppl):S139-46. https://pubmed.ncbi.nlm.nih.gov/8529506

6. Hatziagelaki E, Diamantopoulos E, Halvatsiotis P et al. The effect of a new sulfonylurea glimepiride (HOE 490) on the blood glucose control of type II diabetics. Diabetes Res Clin Pract. 1988; 5(Suppl 1):S481. https://pubmed.ncbi.nlm.nih.gov/2901329

7. Ladik T, Lotz N, Rupp P et al. Efficiency of the new sulfonylurea glimepiride in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 1988; 5(Suppl 1):S487.

9. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs. 1981; 22:211-45. https://pubmed.ncbi.nlm.nih.gov/7021124

10. Defronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med. 1983; 74(Suppl 1A):52-81. https://pubmed.ncbi.nlm.nih.gov/6337486

11. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 1994; 11:223-41. https://pubmed.ncbi.nlm.nih.gov/7848543

13. Kerr CP. Improving outcomes in diabetes: a review of the outpatient care of NIDDM patients. J Fam Pract. 1995; 40:63-75. https://pubmed.ncbi.nlm.nih.gov/7807040

15. Anon. Diabetes mellitus. NIH Cons Dev Conf Statement. 1986; 6:1-7.

16. Blake GH. Control of type II diabetes: reaping the rewards of exercise and weight loss. Postgrad Med. 1992; 92:129-32. https://pubmed.ncbi.nlm.nih.gov/1437899

17. United Kingdom prospective diabetes study group. United Kingdom prospective diabetes study (UKPDS) 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44:1240-58.

18. Expert Committee of the Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. CMAJ. 1992; 147:697-712. https://pubmed.ncbi.nlm.nih.gov/1521215

19. Zimmerman B, Espenshade J, Fujimoto W et al. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995; 18:1510-18. https://pubmed.ncbi.nlm.nih.gov/8722084

20. Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract. 1995; 28(Suppl):S147-9. https://pubmed.ncbi.nlm.nih.gov/8529507

22. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 1994; 343:95-100. https://pubmed.ncbi.nlm.nih.gov/7903785

24. Henry R R. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:97-103. https://pubmed.ncbi.nlm.nih.gov/8554221

26. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334:777-83. https://pubmed.ncbi.nlm.nih.gov/8592553

28. Bailey C, Turner R. Metformin. N Engl J Med. 1996; 334:574-9. https://pubmed.ncbi.nlm.nih.gov/8569826

35. Clark CM Jr. Where do we go from here? Ann Intern Med. 1996; 124(1 Part 2):184-6. Editorial.

44. Lebovitz HE. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med. 1983; 75(Suppl 5B):94-9. https://pubmed.ncbi.nlm.nih.gov/6369972

46. Raskin P. Combination therapy in NIDDM N Engl J Med. 1992; 327:1453-4. Editorial.

47. Yki-Järvinen H, Kauppila M, Kajanssu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992; 327:1426- 33. https://pubmed.ncbi.nlm.nih.gov/1406860

48. Pugh JA, Ramirez G, Wagner ML et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992; 15:953-9. https://pubmed.ncbi.nlm.nih.gov/1387073

49. Roerig. Glucotrol prescribing information. In: Huff BB, ed. Physicians’ desk reference. 43rd ed. Oradell, NJ: Medical Economics Company Inc; 1989:1782-3.

50. Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial: effects on insulin secretory patterns and glucose concentrations. Diabetologia. 1980; 18:49-54. https://pubmed.ncbi.nlm.nih.gov/6988265

54. Bloomgarden ZT. New and traditional treatment of glycemia in NIDDM. Diabetes Care. 1996; 19:295-9. https://pubmed.ncbi.nlm.nih.gov/8742586

57. Turner R, Cull C, Holman R et al. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2):136-45. https://pubmed.ncbi.nlm.nih.gov/8554206

59. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-12. https://pubmed.ncbi.nlm.nih.gov/10359389

60. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. https://pubmed.ncbi.nlm.nih.gov/9742976

61. Nathan DM. Some answers, more controversy, from UKDS. Lancet. 1998; 352:832-3. https://pubmed.ncbi.nlm.nih.gov/9742972

62. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999; 22(Suppl. 1):S27-31.

63. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. https://pubmed.ncbi.nlm.nih.gov/9742977

65. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl.

67. Matthews DR, Cull CA, Stratton RR et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over 6 years. Diabet Med. 1998; 15:297-303. https://pubmed.ncbi.nlm.nih.gov/9585394

68. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. https://pubmed.ncbi.nlm.nih.gov/9827842

97. Chow CC, Sorensen JP, Tsang LWW et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995; 18:307-14. https://pubmed.ncbi.nlm.nih.gov/7555472

102. Kipnes MS, Krosnick a, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111:10-7. https://pubmed.ncbi.nlm.nih.gov/11448655

103. Wolffenbuttel BHR, Gomist R, Squatrito S et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000; 17:40-7. https://pubmed.ncbi.nlm.nih.gov/10691158

104. Chiasson J, Josse R, Hunt J et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994; 121:929-935.

105. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98:443-51. https://pubmed.ncbi.nlm.nih.gov/7733122

106. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab. 1995; 21:256-60.

117. Takeda Pharmaceuticals, Inc. Duetact (pioglitazone hydrochloride and glimepiride) prescribing information. Lexington, MA; 2020 Jun.

118. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72. https://pubmed.ncbi.nlm.nih.gov/16873813

119. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003; 27(Suppl 2):S1-152.

122. Klein S, Allison DB, Heymsfield SB et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007; 30:1647-52. https://pubmed.ncbi.nlm.nih.gov/17360974

123. American Diabetes Association. Summary of revisions for the 2009 clinical practice recommendations. Diabetes Care. 2009; 32:S3-S5. https://pubmed.ncbi.nlm.nih.gov/19118287

124. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008; 358:2630-33. Editorial. https://pubmed.ncbi.nlm.nih.gov/18539918

125. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12. https://pubmed.ncbi.nlm.nih.gov/10938048

126. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. https://pubmed.ncbi.nlm.nih.gov/9831300

127. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009; 32:187-92. https://pubmed.ncbi.nlm.nih.gov/19092168

128. , Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-72. https://pubmed.ncbi.nlm.nih.gov/18539916

129. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59. https://pubmed.ncbi.nlm.nih.gov/18539917

130. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129-39. https://pubmed.ncbi.nlm.nih.gov/19092145

131. American Diabetes Association. Aspirin therapy in diabetes: position statement. Diabetes Care. 2001; 24(Suppl.1):S62-3.

132. Weiss IA, Valiquette G, Schwarcz MD. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes. Cardiol Rev. 2009; 17(4):165-75. https://pubmed.ncbi.nlm.nih.gov/19525678

133. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89. https://pubmed.ncbi.nlm.nih.gov/18784090

134. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643-53. https://pubmed.ncbi.nlm.nih.gov/16371630

135. Skyler JS. Non-insulin-dependent diabetes mellitus: a clinical strategy. Diabetes Care. 1984; 7(Suppl 1):118-29. https://pubmed.ncbi.nlm.nih.gov/6376024

136. Ismail-Beigi F, Moghissi ES. Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocr Pract. 2008 Jul-Aug; 14:639-43.

137. US Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. Rockville, MD; 2010 Sep 23. News release from FDA web site. Accessed 2010 Nov 15. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975

138. Woodcock J (US Food and Drug Administration). Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). Rockville, MD; Available at FDA website. Accessed 2010 Nov 15. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf

139. Food and Drug Administration. FDA drug safety communication: Updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. Rockville, MD; 2011 May 18. Available from FDA website. Accessed 2011 Jun 20. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm

140. Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate and metformin hydrochloride), and Avandaryl (rosiglitazone maleate and glimepiride) tablets risk evaluation and mitigation strategy (REMS). Available from FDA web site. Accessed 2011 Aug 25. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm255624.pdf

141. Food and Drug Administration. FDA advisory committee meeting briefing document for NDA 21071 Avandia (rosiglitazone maleate). Rockville, MD; July 13 and 14, 2010. From FDA website. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf

142. Lipska KJ, Ross JS. Switching from rosiglitazone: thinking outside the class. JAMA. 2011; 305:820-1. https://pubmed.ncbi.nlm.nih.gov/21304068

143. Niemi M, Backman JT, Neuvonen M et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001; 69:194-200. https://pubmed.ncbi.nlm.nih.gov/11309547

144. Niemi M, Kivisto KT, Backman JT. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol. 2000; 50:591-5. https://pubmed.ncbi.nlm.nih.gov/11136298

698. Garber AJ, Handelsman Y, Grunberger G et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2020 executive summary. Endocr Pract. 2020; 26:107-139. https://pubmed.ncbi.nlm.nih.gov/32022600

699. Zelniker TA, Wiviott SD, Raz I et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139:2022-2031. https://pubmed.ncbi.nlm.nih.gov/30786725

704. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020 . Diabetes Care. 2020; 43:S98-S110. https://pubmed.ncbi.nlm.nih.gov/31862752

705. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2020 . Diabetes Care. 2020; 43:S111-S134. https://pubmed.ncbi.nlm.nih.gov/31862753

706. American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2020 . Diabetes Care. 2020; 43:S135-S151. https://pubmed.ncbi.nlm.nih.gov/31862754

707. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025; 48(Suppl 1):S181-S206.

708. Samson SL, Vellanki P, Blonde L et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm-2023 update. Endocr Pract. 2023; 29:305-340.

709. Institute for Safe Medication Practices (ISMP). ISMP list of high-alert medications in acute care settings. ISMP; 2024.